# reload+after+2024-01-23 12:46:33.432282
address1§7380 Coca Cola Drive
address2§Suite 106
city§Hanover
state§MD
zip§21076
country§United States
phone§443 776 3133
fax§443 288 4420
website§https://www.processapharmaceuticals.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. Its pipeline includes three Chemotherapy drugs, including Capecitabine, PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; Gemcitabine, PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers; and Irinotecan, PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.
fullTimeEmployees§15
companyOfficers§[{'maxAge': 1, 'name': 'Dr. David  Young Ph.D., Pharm.D.', 'age': 70, 'title': 'Co-Founder, President of Research and Development & Director', 'yearBorn': 1953, 'fiscalYear': 2022, 'totalPay': 93875, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Patrick  Lin', 'age': 58, 'title': 'Co-Founder, Chief Business & Strategy Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 117153, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Sian E. Bigora Ph.D., Pharm.D.', 'age': 63, 'title': 'Co-Founder and Chief Development & Regulatory Officer', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 120309, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Wendy J. Guy', 'age': 59, 'title': 'Co-Founder, Chief Administrative Officer & Corporate Secretary', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 94188, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. James H. Stanker', 'age': 65, 'title': 'Chief Financial Officer', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 93875, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. George K. Ng Esq., J.D.', 'age': 49, 'title': 'CEO & Director', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.432
currency§USD
dateShortInterest§1702598400
forwardEps§-0.35
pegRatio§-0.06
exchange§NCM
quoteType§EQUITY
shortName§Processa Pharmaceuticals, Inc.
longName§Processa Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1394202600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§84948e47-9710-3f02-b604-b94c873a96b3
gmtOffSetMilliseconds§-18000000
targetHighPrice§4.0
targetLowPrice§4.0
targetMeanPrice§4.0
targetMedianPrice§4.0
recommendationMean§3.0
recommendationKey§hold
numberOfAnalystOpinions§1
quickRatio§8.305
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
